WebJun 1, 2024 · Importance: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival … WebInfigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2024 Oct;6 (10):803-815. Epub 2024 Aug 3. link to original article PubMed.
Experience with Gem/Cis chemotherapy – Cholangiocarcinoma …
http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Gastrointestinal/GIAVPG_Protocol.pdf WebApr 13, 2024 · Researchers are gearing up for a clinical trial that could potentially change how we approach intrahepatic cholangiocarcinoma (ICC) treatment. The phase 2 clinical trial is expected to be completed by December 1, 2024. The study aims to evaluate the safety and efficacy of combining cadonilimab with gemcitabine and cisplatin (Gem/Cis) … 餅 スープ インスタント
Neoadjuvant Gemcitabine Plus Cisplatin With or Without …
WebDec 5, 2013 · One week of cis-gem, gem only a week later, then a week off. Had another CT scan September 20. Liver tumor had shrunk to 17 cm. Yesterday’s CA 19-9 was 61 and alk-phos was 157. Completed my sixth round November 13. Had to take last week off, platelets were 77,000. WebApr 8, 2010 · Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number … As compared with gemcitabine alone, cisplatin plus gemcitabine was associated with a significant survival advantage without the addition of substantial toxicity. WebMar 23, 2024 · Eligible participants will receive cadonilimab (up to 12 months) plus gemcitabine and cisplatin (for maximum of 6-8 cycles) until radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first. The primary endpoint is objective response rate. Study Design Go to tarif txik txak